The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma von Horwitz, S., O'Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Zinzani, P.L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.

Volltext

PRO B: evaluating the effect of an alarm-based patient-reported outcome monitoring compared with usual care in metastatic breast cancer patients-study protocol for a randomised con... von Karsten, Maria Margarete, Kuehn, Friedrich, Pross, Therese, Blohmer, Jens-Uwe, Hage, Anna Maria, Fischer, Felix, Rose, Matthias, Grittner, Ulrike, Gebert, Pimrapat, Ferencz, Julia, Pauler, Luis, Breidenbach, Clara, Kowalski, Christoph

Volltext

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial von Wang, M, Fowler, N, Wagner-Bartak, N, Feng, L, Romaguera, J, Neelapu, S S, Hagemeister, F, Fanale, M, Oki, Y, Pro, B, Shah, J, Thomas, S, Younes, A, Hosing, C, Zhang, L, Newberry, K J, Desai, M, Cheng, N, Badillo, M, Bejarano, M, Chen, Y, Young, K H, Champlin, R, Kwak, L, Fayad, L

Volltext

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome von Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemeister, F.B., Bueso-Ramos, C.E., Zhou, X., McLaughlin, P.W., Fowler, N., Shah, J., Orlowski, R.Z., Samaniego, F., Wang, M., Cortes, J.E., Younes, A., Kwak, L.W., Sarlis, N.J., Romaguera, J.E.

Volltext

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment von Falchook, G. S., Vega, F., Dang, N. H., Samaniego, F., Rodriguez, M. A., Champlin, R. E., Hosing, C., Verstovsek, S., Pro, B.

Volltext

Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology von Mehta‐Shah, N., Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter‐Brown, L., Izutsu, K., Waters, S., Brammer, J. E., Pro, B., Horwitz, S. M.

Volltext

Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL von Tolu, S. S., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A., Shore, T., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., Ruan, J.

Volltext

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA von Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., Piekarz, R.

Volltext

MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL) von Ruan, J., Zain, J. M, Palmer, B., Jovanovic, B. Borko, Mi, X., Swaroop, A., Winter, J., Gordon, L. I, Karmali, R., Pro, B.

Volltext

Utility of (18)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peri... von Horwitz, S. M., Coiffier, Bertrand, Foss, F, Prince, H. M., Sokol, L, Greenwood, M, Caballero, Dolores, Morschhauser, Franck, Pinter-Brown, L, Iyer, S. P., Shustov, A, Nichols, J, Balser, J, Balser, B., Pro, B

Volltext

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.... von Anderlini, Paolo, Saliba, Rima, Acholonu, Sandra, Giralt, Sergio A, Andersson, Borje, Ueno, Naoto T, Hosing, Chitra, Khouri, Issa F, Couriel, Daniel, de Lima, Marcos, Qazilbash, Muzaffar H, Pro, Barbara, Romaguera, Jorge, Fayad, Luis, Hagemeister, Frederick, Younes, Anas, Munsell, Mark F, Champlin, Richard E

Volltext

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma von Esmaeli, B., McLaughlin, P., Pro, B., Samaniego, F., Gayed, I., Hagemeister, F., Romaguera, J., Cabanillas, F., Neelapu, S. S., Banay, R., Fayad, L., Wayne Saville, M., Kwak, L. W.

Volltext

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31) von Conconi, A., Vannata, B., Janikova, A., Ramirez, A., Bodoni, C. Lobetti, Nowakowski, G., Mian, M., Ferreri, Andrés J.M., Ryan, G., Pangalis, G. A., Cabrera, M. E., Luminari, S., Montoto, S., Tsang, R., Aurer, I., Visco, C., Mazzucchelli, L., Trneny, M., Gaidano, G., Federico, M., Lopez‐Guillermo, A., Pro, B., Zucca, E.

Volltext

Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory periph... von Horwitz, S, Coiffier, B, Foss, F, Prince, H M, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Pinter-Brown, L, Iyer, S P, Shustov, A, Nichols, J, Balser, J, Balser, B, Pro, B

Volltext

TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T‐CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST‐HOC ANALYSIS OF THE MAVORIC STUDY von Kim, Y.H., Ortiz‐Romero, P.L., Pro, B., Sokol, L., Scarisbrick, J., Musiek, A., Vermeer, M., Dummer, R., Halwani, A., Fierro, M., Moriya, J., Leoni, M., Bagot, M.

Volltext

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS von Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Jacobsen, E. D., Gritti, G., Pinter‐Brown, L., Isutzu, K., Cohan, D., Daugherty, M., Brammer, J. E., Mehta‐Shah, N., Pro, B., Horwitz, S. M.

Volltext

GSK‐3ß INHIBITOR, 9‐ING‐41 REDUCES CELL VIABILITY AND HALTS PROLIFERATION OF B‐CELL LYMPHOMA von Karmali, R., Chukkapalli, V., Pro, B., Borgia, J.A., Mazar, A., Ugolkov, A., Giles, F.J.

Volltext

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regime... von ANDERLINI, P, SALIBA, R, HOSING, C, COHEN, A, IPPOLITI, C, ROMAGUERA, J, RODRIGUEZ, M. A, PRO, B, FAYAD, L, GOY, A, YOUNES, A, CHAMPLIN, R. E, ACHOLONU, S, OKOROJI, G.-J, DONATO, M, GIRALT, S, ANDERSSON, B, UENO, N. T, KHOURI, I, DE LIMA, M

Volltext

A-254 Comparing Responses to Romidepsin Monotherapy and the Sequential Treatment of Romidepsin Followed by Mogamulizumab for Advanced Cutaneous T-cell Lymphoma von Gordon, E., Lapolla, B., Tolu, S., Amengual, J., Pro, B., Geskin, L.J.

Volltext

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma von Overman, M.J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J.E., Hagemeister, F.B., Kwak, L., Cabanillas, F., Rodriguez, M.A., Fayad, L.E.

Volltext